-

Hologic to Webcast Presentations at Upcoming Investor Conferences

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:

  • 2023 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, September 6 at 9:30 a.m. Eastern Time (ET).
  • Morgan Stanley’s 21st Annual Global Healthcare Conference in New York, NY on Tuesday, September 12 at 9:30 a.m. ET.

Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days following each event.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com

SOURCE: Hologic, Inc.

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Hologic, Inc.

NASDAQ:HOLX

Release Versions
$Cashtags

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Social Media Profiles
More News From Hologic, Inc.

Hologic’s New Sustainability Report Marks 40 Years of Impact

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc., a global leader in women’s health, today released its 2025 Sustainability Report. The new report coincides with Hologic’s 40th anniversary and underscores how the company’s longstanding purpose — to enable healthier lives for women everywhere, every day — continues to drive progress for patients, communities and the planet. “We have always firmly believed that our success as a company is fundamentally tied to our ability and commitment to help...

Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, F...

Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating how the Breast Cancer Index® (BCI™) Test results influence extended endocrine therapy decisions for patients with early-stage, hormone receptor-positive (HR+) breast cancer. According to the latest analysis, physician recommendations for extended endocrine therapy increased by more than 30% among patients identified by the BCI Test as likely to benefit, while reco...
Back to Newsroom